These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32368625)

  • 1. Re-irradiation for oligoprogression under Nivolumab in recurrent head and neck squamous cell carcinoma: A case report.
    Bonomo P; Lucidi S; Desideri I; Scotti V; Casati M; Palomba A; Ciabatti C; Garlatti P; Massi D; Gallo O; Livi L
    Clin Transl Radiat Oncol; 2020 Jul; 23():16-19. PubMed ID: 32368625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.
    Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI
    Swiss Med Wkly; 2018; 148():w14625. PubMed ID: 29756633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab in patients with rare head and neck carcinomas: A single center's experience.
    Kokkali S; Ntokou A; Drizou M; Perdikari K; Makaronis P; Katsarou E; Koufopoulos N; Tzovaras A; Ardavanis A
    Oral Oncol; 2020 Feb; 101():104359. PubMed ID: 31300270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions.
    Kao HF; Lou PJ
    Head Neck; 2019 Oct; 41 Suppl 1():4-18. PubMed ID: 31573752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy.
    Sindhu KK; Nehlsen AD; Lehrer EJ; Rowley JP; Stock RG; Galsky MD; Buckstein M
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of head and neck squamous cell carcinoma (HNSCC). Immune checkpoint blockade.
    Przybylski K; Majchrzak E; Weselik L; Golusiński W
    Otolaryngol Pol; 2018 Sep; 72(6):10-16. PubMed ID: 30647199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [First report on successful application of nivolumab in Hungary for the treatment of locally recurrent head and neck squamous cell carcinoma].
    Bellyei S; Bakó P; Orosz É; Molnár K; Remenár É; Mangel L
    Magy Onkol; 2018 Sep; 62(3):175-178. PubMed ID: 30256884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
    Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergies Radiotherapy-Immunotherapy in Head and Neck Cancers. A New Concept for Radiotherapy Target Volumes-"Immunological Dose Painting".
    Mireştean CC; Crişan A; Buzea C; Iancu RI; Iancu DT
    Medicina (Kaunas); 2020 Dec; 57(1):. PubMed ID: 33374739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
    Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
    Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
    Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
    Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abscopal Effect after Stereotactic Body Radiotherapy with Nivolumab for Lung Metastasis of Head and Neck Cancer: A Case Report.
    Endo M; Fukuda Y; Okada K; Ogawa K; Nakamura M; Takahashi S; Kawahara M; Akahane K; Nagai Y; Yamaguchi H; Nishino H; Mori H; Shirai K
    Case Rep Oncol; 2023; 16(1):1345-1352. PubMed ID: 37946746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
    Szturz P; Vermorken JB
    BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
    Zargar M; McFarlane T; Chan KKW; Wong WWL
    Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab.
    Schwab KS; Kristiansen G; Schild HH; Held SEA; Heine A; Brossart P
    Case Rep Oncol; 2018; 11(1):17-20. PubMed ID: 29515404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in head and neck cancer: The great challenge of patient selection.
    Napolitano M; Schipilliti FM; Trudu L; Bertolini F
    Crit Rev Oncol Hematol; 2019 Dec; 144():102829. PubMed ID: 31739116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
    Kok VC
    Front Oncol; 2020; 10():268. PubMed ID: 32185135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
    Matsuo M; Yasumatsu R; Masuda M; Toh S; Wakasaki T; Hashimoto K; Taura M; Uchi R; Nakagawa T
    Oral Oncol; 2020 Feb; 101():104525. PubMed ID: 31863963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebral Infarction as a Rare Adverse Event of Immune Checkpoint Inhibitors in Patients With Head and Neck Squamous Cell Carcinoma: A Case Series.
    Inoue T; Kumai T; Ohara K; Takahara M
    Cureus; 2023 Oct; 15(10):e47406. PubMed ID: 38021593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.